1.	A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081014, NCT01154140
2.	A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: A8081029, NCT01639001
3.	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
4.	Crizotinib and STA-9090 in ALK Positive Lung Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-015, NCT01579994
5.	A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AT13387-05, 2012-001575-37, NCT01712217
6.	An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081005, NCT00932451
7.	CREATE: Cross-tumoral Phase 2 With Crizotinib Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 15 and over Sponsor: Other Protocol IDs: EORTC-90101, 2011-001988-52, NCT01524926
8.	Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2013-00737, RTOG 1306, U10CA021661, NCT01822496
9.	A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081001, NCT00585195
10.	A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081006, NCT01121575
11.	An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081013, PROFILE 1013, NCT01121588
12.	Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer Phase: Phase I Type: Treatment Status: Active Age: not specified Sponsor: Other Protocol IDs: 2011-1142, NCT01548144
13.	Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081012, NCT01576406
14.	Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 13 months to 21 years Sponsor: NCI, Other Protocol IDs: ADVL1212, NCI-2012-01968, U01CA097452, COG-ADVL1212, NCT01606878
15.	Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: SJHG12, NCT01644773
16.	Dasatinib and Crizotinib in Advanced Cancer Phase: Phase I Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2012-0721, NCT01744652
17.	Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation Phase: No phase specified Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: 201204080RIC, NCT01637597